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CORTISOL EXERTS BI-PHASIC REGULATION OF INFLAMMATION IN
HUMANS

Mark P. Yeager, MD 䊐 Department of Anesthesiology and Critical Care
Medicine, Dartmouth-Hitchcock Medical Center
Patricia A. Pioli, PhD, Paul M. Guyre, PhD
Dartmouth Medical School

䊐

Department of Physiology,

䊐 Natural and synthetic glucocorticoids (GCs) have been used for decades to suppress
inflammation. In this paper, we re-examine the role of the endogenous GC, cortisol, as a
primary homeostatic regulator of the human inflammatory response to injury. Our data
show that cortisol regulation of innate immunity can be both pro-inflammatory and antiinflammatory. Using a human model of in vivo cortisol depletion, we first show that baseline (diurnal) cortisol concentrations do not exert an anti-inflammatory effect. This is the
first clue that cortisol regulation of inflammation is not represented by a linear doseresponse relationship. We next show in surgical patients that cortisol does exert an acute
anti-inflammatory effect over a carefully regulated range of physiologic cortisol concentrations. Finally, transient pre-treatment of healthy humans with cortisol induces a bi-phasic response during a later, delayed systemic inflammatory response: an intermediate cortisol concentration augments inflammation while a high cortisol concentration is neither
pro- nor anti-inflammatory. Based on these findings and the work of others, we propose a
new paradigm that identifies cortisol regulation of human inflammation as both dualistic—it is pro- and anti-inflammatory—and dynamic, it evolves over time.
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INTRODUCTION

Glucocorticoids (GCs) have been widely used to suppress inflammation since 1949 when Hench et al surprised most of the biomedical community by reporting that GCs have anti-inflammatory effects in human
disease (Hench et al. 1949). Since then, most GC research has focused on
the anti-inflammatory and immune suppressive properties of GCs, while
comparatively little research has examined the stimulatory properties of
GCs that were discovered by Hans Selye and others and that were, in fact,
widely acknowledged prior to 1949 (Selye et al. 1940; Selye 1944).
Recently, investigators have re-examined the stimulatory effects of GCs
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on inflammatory defense mechanisms (Yeager et al. 2004, Sorrells and
Sapolsky 2010). Recent reports show that GCs induce increased cellular
expression of receptors for several pro-inflammatory cytokines including
interleukin (IL)-1 (Spriggs et al. 1990), IL-2 (Wiegers et al. 1995), IL-4
(Paterson et al. 1994), IL-6 (Snyers et al. 1990), and IFN-g (Strickland et
al. 1986), as well as GM-CSF (Hawrylowicz et al. 1994). GCs have also been
shown to stimulate effector cell functions including phagocytosis by
monocytes (van der Goes et al. 2000), effector cell proliferative responses
(Spriggs et al. 1990), macrophage activation (Sorrells and Sapolsky 2010),
and a delay of neutrophil apoptosis (Cox 1995).
The fundamental importance of GCs in human physiology is powerfully demonstrated by several observations including; regulation of GC synthesis at the brain diencephalic level, the rapid release of GCs in response
to any external injury or threat of injury, and by the widespread distribution of intracellular receptors for GCs (GR) in virtually every somatic cell
in the body. To account for the well-known suppressive and the less wellknown stimulatory effects of GCs on inflammatory processes, we have proposed a model of GC action that describes a concentration-dependent, biphasic (both stimulatory and suppressive) GC regulation of in vivo defense
mechanisms (Munck et al. 1984; Yeager et al. 2004) (Figure 1). The model
is derived from work completed by many researchers who investigated, initially, the stimulatory properties of GCs and, since 1949, the suppressive

FIGURE 1. The figure shows a bi-phasic model of GC regulation of in vivo defense mechanisms,
including innate immune inflammation. According to this model, basal concentrations of cortisol are
not anti-inflammatory but exert a supportive (permissive) action on various defense mechanisms. As
cortisol concentrations increase to those associated with systemic stress or pharmacological administration of cortisol, a bi-phasic relationship is observed, especially when there is a time delay between
the increase in cortisol concentration and the inflammatory stimulus.
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actions of GCs. According to this model, normal diurnal concentrations of
GCs support the activity of defense mechanisms in a permissive manner,
while higher stress-induced concentrations act acutely to suppress inflammation and prevent tissue injury from an excessive or prolonged inflammatory response. Both activities are mediated by the GC intracellular
receptor, GR, in a concentration-dependent agonist-receptor mechanism.
The model further proposes that stress concentrations of cortisol also exert
a delayed (time-dependent) preparative effect that is stimulatory. Recent
studies have, in fact, demonstrated bi-directional effects of GCs on specific
effector cell functions depending on GC concentration. Such effects have
been shown for inflammatory cytokine release from monocytes, phagocytosis by macrophages, the acute phase protein response, delayed type
hypersensitivity reactions and wound healing (Dhabhar and McEwen 1999;
Dinkel et al. 2003; Yeager et al. 2004; Viswanathan and Dhabhar 2005; Lim
et al. 2007). These reports identify a concentration- and time-dependent
range of GC effects that are both pro- and anti-inflammatory. Due to the
manifest clinical implications for pro-inflammatory GC regulation of the
human injury response, we have used several clinical research paradigms to
examine the clinical consequences of GC-induced enhancement of the
human inflammatory response to injury.
METHODS
Human subjects.

All research involving human subjects was approved by the
Dartmouth College Committee for the Protection of Human Subjects
(Institutional Review Board) and written; informed consent was obtained
from all participants.
Laboratory Techniques.

Monocyte isolation.
Mononuclear cells were isolated by ficoll-hypaque density gradient
(Histopaque 1077, Sigma-Aldrich, St. Louis, MO). Monocytes were positively selected from mononuclear cells with anti-CD14 magnetic beads
(Miltenyi Biotec Inc. Auburn, CA); purity was always greater than 95%.
Treatments and their duration were as noted in the Results.
Cytokine analysis.
Samples were collected and frozen at –80˚C for batched measurement
of TNFa, IL-6 and IL-10 concentrations. TNFa was measured using a
TNFa sandwich ELISA (paired antibodies, BD Biosciences Pharmingen,
San Diego, CA). IL-6 levels were determined using an IL-6 ELISA kit
(Peprotech, Rocky Hill, NJ). IL-10 was measured using an IL-10 ELISA kit
(Biosource, Camarillo, CA).
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Cell staining and flow cytometry.
Following culture and treatments, washed monocytes were stained for
surface expression of CD54, CD119 and CD163 (FITC-labeled anti-CD54
and FITC-labeled anti-CD119, R&D Systems, Minneapolis, MN; PElabeled anti-CD163, Trillium Diagnostics, Bangor, ME. Cells were analyzed by flow cytometry on a FACSCAN flow cytometer and monocytes
were gated on forward/side scatter to eliminate dead cells (<5%) from
the analysis. Mean fluorescent intensity (MFI) was determined by the geometric mean of the fluorescence of gated monocytes.
Messenger RNA (mRNA) isolation and quantification.
Total RNA was extracted from peripheral blood monocytes using
RNeasy mini columns (Qiagen). RNA samples were treated with RNasefree DNase prior to amplification. RNA integrity and concentration were
determined with RNA6000 Nano LabChip kit (Agilent). Using 500 ng of
RNA as template, first-strand cDNA was synthesized using random hexamers and SuperScript II Moloney murine leukemia virus reverse transcriptase (Invitrogen). Expression of mRNA was quantified by Taqman
PCR. cDNA (0.5 µl/well) was transferred into 96-well format plates, and
Taqman Master Mix (Applied Biosystems) was added. Taqman-validated
primers and Taqman MGB probes (labeled with fluorescent reporter dye
6FAM) were used for amplification of genes. Data were analyzed using
ABI 7300 quantification software (Applied Biosystems) and are expressed
as relative mRNA levels.
Cortisol.
Total plasma cortisol was measured on an Immulite® analyzer using a
DPC Cortisol kit (Los Angeles, CA). Salivary free cortisol, as a measure of
active free cortisol at in vivo effector cell sites, was measured by
Salimetrics® Expanded Range High Sensitivity Salivary Cortisol Enzyme
Immunoassay Kit (State College, PA).
ACTH.
Plasma ACTH was measured by solid-phase chemiluminscent assay
(Immulite®, Diagnostic Products Corporation).
Statistical Analysis.

The primary end-point for most studies was the cytokine response to
endotoxin stimulation assessed by ELISA. Power analyses for clinical studies were calculated using differences in endotoxin-stimulated IL-6 concentrations between control and treatment conditions. Non-parametric
rank tests and Student’s t-tests, with appropriate transformation to normality, were used to compare control and treatment conditions at each
time period or treatment condition. To account for the correlated nature
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of the data that resulted from multiple measures when subjects were tested over time, we used generalized estimating equations (GEE) as the primary analytic tool for inter-group comparisons that consider all time
points and to characterize changes over time. A p-value less than 0.05 was
taken to indicate statistical significance without adjustment for multiple
comparisons.
RESULTS
1. Basal (diurnal) cortisol concentrations do not exert an anti-inflammatory effect in vivo.

In this study, 8 healthy human subjects (6 male: 2 female), ages 19-47,
were treated on Day 1 with a pharmacologically-induced depletion of
endogenous cortisol activity for approximately 24 hours. Depletion of
cortisol activity was achieved with 200 mg of the GR antagonist RU486
(Mifeprex®; Danco Laboratories, NY) orally at 0400 and 1600 hours and
an intravenous infusion of the adrenal cortical synthesis inhibitor, etomidate, at 1.5mg/kg/hr from 0900hr to 2100hr to suppress endogenous
synthesis of cortisol (Yeager et al. 2008). Peripheral blood samples were
taken at 0900 the day before (Day 1) and the day after (Day 3) the cortisol depletion treatment. Total plasma and salivary free cortisol concentrations confirmed significant decreases in endogenous cortisol concentrations by 4 PM on Day 1 following the cortisol “depletion” (control 5.3
[+/- 1.0 S.E.] ug/dl vs. depletion 1.8 [+/-0.6 S.E.] ug/dl total plasma cortisol and control 3.9 [+/- 1.6 S.E.] nM vs. depletion 1.5 [+/- 0.6 S.E.] nM
salivary free cortisol ;p<0.001 control vs. depletion for both). In addition,
plasma adrenocorticotrophic hormone (ACTH) concentrations
increased on the morning of Day 3 to approximately 10 times baseline
values on Day -1 (16.5 pg/ml +/- 2.9 S.E. vs. 138 pg/ml +/- 28 pg/ml;
p<0.001) indicating physiologically significant cortisol depletion
(Figure 2). Monocytes were isolated on the day before cortisol depletion
and the day after depletion. Monocytes were tested for inflammatory
responsiveness by stimulating cells ex vivo with bacterial lipopolysaccharide (LPS) at a concentration of1 ng/ml and measuring cellular release
of tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6) and interleukin-10 (IL-10), as well as cellular expression of the GC-inducible molecules CD54 and CD163. Monocytes showed no difference in their
inflammatory responses to LPS following cortisol depletion (TNF-a =
1083pg/ml before vs. 911 pg/ml after depletion; IL-6 = 1734 pg/ml
before vs. 1749 pg/ml after depletion; IL-10 = 171 pg/ml before vs. 57
pg/ml after depletion; p = n.s. for all).
These findings had 2 implications with regard to the design of further
studies: First, the data show that basal (diurnal) concentrations of cortisol do not exert an anti-inflammatory effect on several pro-and anti336
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FIGURE 2. Plasma adrenocortiocotrophic hormone (ACTH) concentrations before, during and
after a cortisol depletion treatment that included 2 doses of the glucocorticoid receptor antagonist,
RU486 at 0400 and 1600 hours and an intravenous infusion of the adrenal cortical synthesis inhibitor,
etomidate, from 0900 to 2100 hours. ACTH concentrations are compared to those observed with an
intravenous saline treatment (Control) and treatment with pharmacological doses of cortisol (High
Cortisol) (Note that intravenous cortisol treatment began at 0900 of Day 2, after the second ACTH
measurement made at 0830 on that day). Note that, following the cortisol depletion treatment,
ACTH concentrations increase by almost an order of magnitude (note different scales for ACTH)
indicating significant depletion of effective cortisol concentrations.

inflammatory mediators of the human immune inflammatory response.
This finding supports the need for the innate immune system to maintain
a ‘hair trigger’ response pattern in order to rapidly isolate and limit bacterial invasion following disruption of tissue integrity by physical injury.
Most GC-mediated effects are genomic and take hours to find expression
at the protein level. This is too long an interval for effective control of
bacterial replication that can take place in a much shorter time span.
Second, these data also provide a clue that GC regulation of inflammation may not be a simple matter of straightforward, concentrationdependent suppression of inflammatory responses since withdrawal of
cortisol activity in vivo did not lead to increased inflammatory responsiveness of immune effector cells.
2. Cortisol exerts bi-directional regulation of monocyte mRNA for inflammatory mediators including GR, interleukin-10 (IL-10) and Suppressor of
Cytokine Synthesis 3 (SOCS3).

The same subjects also received, at separate times following a washout interval, either intravenous saline for 8 hours (Control) from 0900 to
1700 hours or a high dose of intravenous cortisol (hydrocortisone
[SoluCortef, Upjohn] @ 8 ug//kg/min) for 8 hours (followed by oral
hydrocortisone overnight) to raise plasma cortisol concentrations to
high, pharmacological concentrations for approximately 24 hours.
Monocytes were isolated from peripheral blood before and after each
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treatment, mRNA was extracted and analyzed for comparison between
groups. In keeping with the well-known anti-inflammatory effects of GCs,
mRNA for the anti-inflammatory cytokine IL-10 was regulated in concentration-dependent manner with decreased IL-10 mRNA following cortisol
depletion and increased mRNA following high dose cortisol exposure.
However, we also found regulation of other key molecules had more complex implications. We found, for example, that mRNA for GR alpha, the
dominant GC receptor protein, was decreased following exposure to high
dose cortisol, which has been previously reported (Burnstein et al. 1991),
but that GR mRNA was also increased following the in vivo cortisol depletion treatment (Figure 3a). The latter result is an entirely new finding.
Given the multiplicity of cellular events that are regulated by GCs, the

FIGURE 3. Following each of 3 in vivo treatments (Control, High Cortisol, Low Cortisol), monocytes
were isolated from peripheral blood and incubated for 3 hours in either media alone or media supplemented with 1 ng/ml LPS. Messenger RNA levels were then determined for the glucocorticoid
receptor (GR) (Figure 3a) and Suppressor of Cytokine Synthesis-3 (SOCS3) Figure 3b. GR mRNA
levels were increased significantly by in vivo Low Cortisol and decreased by in vivo High Cortisol treatment. SOCS3 mRNA levels increased significantly following Low Cortisol treatment in stimulated
cells. *** = p < 0.001 vs. control cells under similar conditions.

338

Cortisol regulation of inflammation

clinical implications of a bi-directional regulation of GRa by cortisol are
not only unexplored, they cannot be predicted to follow a linear doseresponse relationship with in vivo cortisol concentrations. The latter
point is underscored by our finding that mRNA for a recently described
key suppressor of inflammatory cytokine synthesis (SOCS3) was increased
in monocytes following the cortisol depletion treatment (Figure 3b). This
finding would suggest that depletion of cortisol could lead to an inhibition of some inflammatory responses if a key suppressor of inflammatory
mediators is increased. These findings again are consistent with, though
they do not clearly demonstrate bi-phasic GC regulation of human
inflammation.
3. Cortisol exerts an acute, concentration-dependent, acute anti-inflammatory effect over the physiologic range of cortisol.

Based on our model of GC action that proposes a bell-shaped curve
for GC regulation of in vivo defense mechanisms, we designed a study in
which we carefully regulated cortisol concentrations from low to high
during an acute systemic inflammatory stimulus. We studied patients
scheduled to undergo cardiac surgery with cardiopulmonary bypass,
which is known to induce a substantial and well-described systemic
inflammatory response (Laffrey and Cheng 2002). We chose to measure
plasma IL-6 as a marker of the pro-inflammatory response to surgery
because it is released into the circulation in substantial quantities and
because elevated IL-6 concentrations persist for several days after surgery.
Sixty patients were randomly divided into equal groups of 10. Patients
were administered 2 doses of etomidate during surgery to suppress
endogenous cortisol synthesis while each group was then administered
varying doses of cortisol immediately before and during surgery to control cortisol concentrations at pre-determined levels. A Control Group
received no etomidate and intravenous saline. We were able to successfully regulate plasma cortisol concentrations during and immediately
after cardiac surgery through the desired range from low (5-10 ug/dl) to
‘normal’ (15-20 ug/dl), to stress-associated concentrations (35-45 ug/dl),
to high pharmacologic (non-physiological) concentrations (70-80
ug/dl). The results showed that cortisol exerted a concentration-dependent suppression of the systemic inflammatory IL-6 response to cardiac
surgery (Figure 4). We also found, interestingly, that maximal suppression of inflammation was achieved by a stress-associated, but still physiologic, cortisol concentration. There was no greater anti-inflammatory
effect at higher cortisol concentrations (Yeager et al. 2005) although IL10 concentrations continued to increase with increasing cortisol concentrations as we and others have shown (Fillinger et al. 2002, Weis 2009).
The well-described anti-inflammatory effects of GCs would indeed
predict a concentration-dependent suppression of the pro-inflammatory
339
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FIGURE 4. Cardiac surgical patients (n=60) were randomly divided into 6 groups before surgery.
Treatment groups received intravenous etomidate during surgery to suppress endogenous cortisol
synthesis. Varying doses of cortisol were then administered for 6 hours before and during surgery to
regulate plasma cortisol concentrations over the physiologic range. Plasma cortisol concentration at
the end of the cortisol infusion is plotted against peak plasma IL-6 concentrations that were observed
4 hours after surgery. The results show a classic dose-response relationship between the pro-inflammatory cytokine, IL-6, and the acute plasma cortisol concentration.

response to cardiac surgery as shown here. However, in this study we carefully controlled endogenous cortisol release during an acute inflammatory stimulus in order to manipulate cortisol concentrations through the
relevant physiological range from low to high. We were able to effectively control cortisol concentrations by suppressing endogenous synthesis
and adding back varying doses of cortisol. This was an important step in
defining the scope of cortisol effects on human inflammation. We found
that, acutely, physiological cortisol concentrations are anti-inflammatory
and, as proposed, act to limit over expression of an inflammatory
response that could lead to tissue damage (Munck and Naray-Fejes-Toth
1994). We next looked for delayed, preparative (pro-inflammatory)
effects of stress cortisol concentrations in vivo.
4. Cortisol exerts a delayed bi-phasic regulation of systemic inflammation
with pro-inflammatory effects that are maximal at an intermediate cortisol
concentration.

Most of the in vivo animal studies that have shown pro-inflammatory
effects of GCs have observed increased inflammation only when there is
a time interval between the in vivo exposure to GCs and the subsequent
pro-inflammatory stimulus. In this study, healthy human subjects (n=36)
were randomly divided on Day 1 into 3 treatment groups: 1) A Control
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Group that received intravenous saline for 6 hours from 0900 to 1500
hours. 2) A Stress Cortisol group that received intravenous hydrocortisone at 1.5 ug/kg/min for the same time period. (This dose was designed
to increase plasma cortisol concentrations to the range that is typically
observed after a major physical stress [~30-50 ug/dl]). 3) A
Pharmacologic Cortisol group that received 3 ug/kg/min for 6 hours to
raise plasma cortisol concentrations to a level that is usually observed only
when exogenous cortisol is administered. The 6-hour time period corresponds to the approximate duration of elevated cortisol that is observed
in humans after an isolated systemic inflammatory stimulus, in this case
LPS (Rassias et al. 2005). The following day, subjects received 2ng/kg
intravenous LPS to induce a transient systemic inflammatory response
followed by serial sampling of peripheral blood. Subjects in all groups
were matched for age, gender and weight. All subjects experienced a
transient systemic inflammatory response as previously described
(Suffredini et al. 1999) that included sequential increases in plasma concentrations of pro-inflammatory IL-6 and anti-inflammatory IL-10. In the
Stress Cortisol group, the pro-inflammatory IL-6 response was significantly increased compared to both the Control and Pharmacologic
Cortisol groups while the anti-inflammatory IL-10 response was
decreased (Yeager et al. 2009). We compared the salivary free cortisol concentration that was achieved in vivo during the 6-hour intravenous infusion (Day1) with both the peak IL-6 concentrations (3 hours after LPS
injection) and with the total area under curve (AUC) for IL-6 over 8
hours after LPS injection (Day 2). We found clear evidence that cortisol
induced a bi-phasic regulatory effect on the pro-inflammatory response
to LPS (Figure 5). Peak pro-inflammatory effects of cortisol were
observed at the intermediate cortisol concentration that is typically
observed during a major systemic stress. Higher and lower cortisol concentrations did not have the same effect. Notably, the higher dose cortisol exposure did not lead to a significantly greater pro- or anti-inflammatory effect compared to the control group. Clinically, the heart rate and
temperature profiles suggested that a greater IL-6 response in the Stress
Cortisol group led to a greater physical response to LPS, however there
were no statistically significant differences between the 3 groups.
The results of this study are in accordance with animal studies that
have shown both time- and concentration-dependent bi-phasic regulation
of inflammation in animals in vivo. These results suggest, for the first
time, a similar effect in humans. Acutely, cortisol has anti-inflammatory
effects following a systemic inflammatory stimulus (Figure 4). However, a
cortisol concentration that acts acutely to suppress systemic inflammation
also has a delayed effect of augmenting the inflammatory response to
subsequent, delayed stimulus (Figure 5). These data provide strong evidence of an adaptational role for stress-associated concentrations of cor341

M. P. Yeager and others

FIGURE 5. Healthy human volunteers received 1 of 3 treatments the day before an intravenous injection of bacterial lipopolysaccharide (LPS): Intravenous saline for 6 hours from 0900 to 1500 hr, intravenous hydrocortisone @ 1.5ug/kg/min for 6 hours (Stress), or intravenous hydrocortisone @ 3.0
ug/kg/min (Pharm) for 6 hours. At the end of the 6 hour infusion, salivary free cortisol concentrations were measured. The next day, subjects received intravenous LPS to induce a transient systemic
inflammatory response and serial testing of plasma IL-6 was performed for 8 hours. An intermediate
(stress-associated) concentration of cortisol augmented the IL-6 response to LPS compared to lower
control concentrations or higher, pharmacologic concentrations.

tisol in humans. Notably, higher cortisol concentrations (pharmacologic
concentrations) did not have the same effect.
DISCUSSION

Research on GCs has traditionally been guided by a uni-dimensional
paradigm in which GCs are considered to exert an anti-inflammatory
action with a linear dose-response relationship: too little GC leads to
excess inflammation and too much GC impairs inflammatory processes
necessary to prevent infection and repair injured tissue. Recent work conducted primarily in vitro and in animals, has demonstrated a more complex relationship between GCs and immune-mediated inflammation. It is
now increasingly clear that; 1) GCs can exert pro-inflammatory effects on
key inflammatory processes and, 2) GC regulation of inflammation can
vary from anti- to a pro-inflammatory in a time-dependent manner. These
observations add a new perspective that is critical to understanding the
regulation of inflammation in humans. The goal of this research was to
identify and assess the potential clinical implications of GC enhancement
of innate immune inflammation. Inflammatory processes and inflammatory symptoms account for a substantial proportion of human disease.
Given the central role that GCs have in the regulation of inflammation,
this new paradigm of GC-mediated inflammatory regulation could have
widespread implications for understanding and treating human disease.
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We previously proposed a unifying physiological model of GC action
that integrates the well-known anti-inflammatory properties of GCs with
the emerging data on their ‘preparative’ effects (Figure 1). The model
predicts that GC effects on a stimulus-induced inflammatory response
can be EITHER suppressive OR stimulatory in a concentration- and timedependent manner. The immediate in vivo effect of both stress-induced
and pharmacological GC concentrations is to suppress concurrent
inflammation and protect the organism from an excessive or prolonged
inflammatory response. Time is integral to the model, which predicts
delayed preparative effects of GCs that will be maximal following intermediate increases in GC concentration and less prominent at higher or
lower concentrations. These preparative effects would be expected to
enhance an organism’s response to a subsequent inflammatory stimulus
and thus increase resistance to disease in an adaptational manner. The
data cited above clearly support this model of GC control of inflammation with regard to the function of monocytes and perhaps other effector
cells as well.
GCs alone, in the absence of an inflammatory stimulus, up-regulate
monocyte mRNA and/or receptors for several molecules that participate
in pro-inflammatory signaling, as noted above and in the studies presented here. However, these upregulatory effects are typically not
observed at the protein level in the absence of a succeeding inflammatory stimulus, presumably to avoid needless expenditure of cellular
resources. The distinction between GC effects in the presence or absence
of an inflammatory stimulus is important because it defines the distinction between acute GC effects on inflammation that are anti-inflammatory and delayed (preparative) effects that can be stimulatory or proinflammatory. In humans, as shown here, if in vivo GC concentrations are
elevated concurrent with an inflammatory stimulus, anti-inflammatory
effects are observed. In sharp contrast, with a time delay of 12 or more
hours between an increased GC concentration and the onset of an
inflammatory stimulus, enhancing effects on inflammation are observed.
These effects have been shown to persist in humans for up to 6 days
(Barber et al. 1993). Similarly, in rats, GCs lead to enhanced LPS-induced
release of inflammatory cytokines, but only during a defined time window
after GC exposure (Fantuzzi et al. 1995, Frank et al. 2009). Also,
betamethasone given to pregnant ewes increases LPS-induced fetal lung
inflammation 5 days after, but not 2 days after the GC administration
(Kallapur et al. 2003). In another interesting parallel, mice exposed to the
stress of a sterile burn develop increased resistance to subsequent E. coli
sepsis in a time-dependent manner that is first observed following a delay
of 1 day and peaks at 7 days after the burn injury. This effect was associated with enhanced response of cellular LPS signaling mediators (Maung
et al. 2008).
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We also showed that GC-induced enhancement of inflammatory
responses is maximal at an intermediate concentration, in our studies at
a concentration that approximates that observed in vivo following a major
systemic inflammatory stimulus. Similar data have been recently reported
in vitro and in vivo in animals. For example, peritoneal macrophages show
a 2- to 4-fold enhancement of Fc receptor-mediated phagocytosis when
co-incubated with 10 to 100 nM hydrocortisone, but higher or lower concentrations were less effective (Warren and Vogel 1985). Co-incubation of
bone marrow-derived macrophages with corticosterone (CS) leads to a
dose-dependent increase in LPS-stimulated TNF-a and IL-6 release that is
maximal (and only observed) at intermediated CS concentrations of 1020 nM (Zhang and Daynes 2007a). A similar result was observed in mice
implanted with CS pellets (serum CS concentrations ~ 5-6 nM) and in
11B-hydroxysteroid dehydrogenase type-1 deficient knock-out mice that
have increased circulating plasma CS compared to wild-type controls
(Zhang and Daynes 2007b). Of note, the enhanced cytokine response was
associated with augmented signaling by NFkB and MAPKs, prime mediators of LPS induced inflammation and targets for GC regulation of
inflammation (Smyth et al. 2004). Other in vivo studies report tantalizing
similarities but lack information on effective GC concentrations, effector
cell populations involved, and mechanisms. For example, an intermediate CS concentration leads to enhanced wound healing (burst strength of
intestinal anastamoses) after surgery in rats (Matsusue and Walser 1992).
Similarly, low but not high GC pretreatment of rats leads to enhancement
of a subsequent adaptive immune response that is associated with
increased trafficking of leukocytes into inflammatory sites (Viswanathan
and Dhabhar 2005).
In addition to enhanced responses to LPS, recently identified proinflammatory effects of GCs also show enhanced localization of effector
cells at inflammatory sites. It has been known for some time that GCs
alone induce a rapid and profound monocytopenia in humans (Calvano
et al. 1987), but the potential mechanisms and consequences of GCinduced monocytopenia remained largely unstudied until recently. We
now know that GCs, including cortisol, enhance expression of the
chemokine receptor CCR2 on human monocytes in association with
enhanced monocyte migration towards the chemotactic CCR2 ligand,
CCL2 (MCP-1) (Penton-Rol et al. 1999; Okutsu et al. 2008). Related studies have shown GC enhancement of the monocyte migratory response to
the complement fraction C5a (Pieters et al. 1995) as well as increased
adherence to endothelial cells (Wenzel et al. 1996). Carefully conducted
studies in animals have also revealed important consequences of these
regulatory effects including enhanced adaptive immune responses to
local antigen injection (Lyte et al. 1990; Dhabhar et al. 1996; Fleshner et
al. 1998) and enhanced local inflammation in tissue injury models
344
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(Dinkel et al. 2003; Viswanathan and Dhabhar 2005). The in vivo inflammatory endpoints in all these studies have been tightly linked to GCinduced redistribution of effector cells, especially monocytes, to inflammatory sites. The significance of these findings in humans has yet to be
established.
Based on the recent literature and the results reported here, we
hypothesize that pre-exposure to stress-associated cortisol concentrations
“prime” effector cells of the monocyte/macrophage lineage for an augmented pro-inflammatory response by; a) inducing preparative changes
in key regulators of LPS signal transduction, and b) enhancing localization of inflammatory effector cells at potential sites of injury. These
effects are maximal at an intermediate cortisol concentration, are only
observed following a delay of 12-24 hours, and are most prominent in the
presence of a delayed inflammatory stimulus. This hypothesis is the subject of ongoing investigations that focus on the cellular signaling pathways for LPS. The clinical implications of these findings have yet to be
explored. In the setting of chronic inflammation or stress, where elevated GC concentrations are sustained, existing models of GC action are
applicable. However, in the setting of repetitive stress or injury, these new
data may provide an explanation for the development of resistance to disease and ultimately, functional decline, as originally shown by Selye.
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